Page last updated: 2024-10-29

ifosfamide and Cancer of the Uterus

ifosfamide has been researched along with Cancer of the Uterus in 76 studies

Research Excerpts

ExcerptRelevanceReference
"This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS)."9.51Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. ( Copeland, LJ; DiSilvestro, PA; Filiaci, VL; Hensley, ML; Huang, HQ; Ioffe, OB; Miller, DS; Moore, KN; Mutch, DG; Powell, MA; Santin, A; Secord, AA; Spirtos, NM; Tewari, KS; Warshal, DP, 2022)
"To determine if paclitaxel added to ifosfamide as first-line treatment for advanced uterine carcinosarcoma (CS) improves overall survival (OS), progression-free survival (PFS), response, and toxicity."9.12Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. ( Bitterman, P; Eaton, L; Filiaci, V; Homesley, HD; Kilgore, LC; Markman, M; Monk, BJ; Ueland, FR, 2007)
"Adjuvant ifosfamide and cisplatin after primary surgery for stage I or II carcinosarcoma of the uterus is tolerable."9.11Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. ( Carson, LF; Gallion, H; Kauderer, J; Lentz, SS; Sutton, G; Whitney, CW, 2005)
"The aims of this study were to substantiate the previously reported activity of ifosfamide in patients with advanced, persistent, or recurrent carcinosarcoma (mixed mesodermal sarcoma) of the uterus, and to determine whether the addition of cisplatin results in an improved response or survival."9.09A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. ( Brunetto, VL; Hsiu, JG; Kilgore, L; Lentz, SS; McGehee, R; Olt, G; Soper, JT; Sorosky, J; Sutton, G, 2000)
"This is a Phase II groupwide study of the Gynecologic Oncology Group (GOG) to determine the toxicity and efficacy of a combination of ifosfamide and doxorubicin in patients with advanced or metastatic leiomyosarcomas of the uterus who had not received other chemotherapy."9.08Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. ( Blessing, JA; Malfetano, JH; Sutton, G, 1996)
"A retrospective study to evaluate six cycles of cisplatin 40 mg/m2 on day 1 and ifosfamide 1,200 mg/m2 daily on days 1 to 4 with Mesna every four weeks as first line treatment for 29 patients with a diagnosis of uterine carcinosarcoma."7.83Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( Abu-Khalaf, MM; Azodi, M; Hatzis, C; Higgins, S; Lin, K; Ratner, E; Raza, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Wang, H, 2016)
"To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management."7.76Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010)
"To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas."7.73Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. ( Piura, B; Rabinovich, A, 2005)
" In this article we report the first case of methemoglobinemia in a patient with metastatic uterine leiomyosarcoma, after infusion of ifosfamide chemotherapy."7.70Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. ( Govert, JA; Hadjiliadis, D, 2000)
"Between 1992 and 1999, 13 consecutive patients with completely resected moderate- to high-grade uterine sarcoma received three cycles of adjuvant ifosfamide (1."7.70Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. ( Belinson, JL; Kennedy, AW; Kushner, DM; Markman, M; Rybicki, LA; Webster, KD, 2000)
"The purpose of this study was to evaluate the activity of ifosfamide (isophosphamide) in patients with advanced or recurrent leiomyosarcoma not previously exposed to chemotherapy."7.68Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. ( Barrett, RJ; Blessing, JA; McGehee, R; Sutton, GP, 1992)
"This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS)."5.51Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. ( Copeland, LJ; DiSilvestro, PA; Filiaci, VL; Hensley, ML; Huang, HQ; Ioffe, OB; Miller, DS; Moore, KN; Mutch, DG; Powell, MA; Santin, A; Secord, AA; Spirtos, NM; Tewari, KS; Warshal, DP, 2022)
" So we compared VAC protocol and ifosfamiide for toxic effects."5.30Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide). ( Erman, O; Simşek, T; Trak, B; Uner, M; Zorlu, GC, 1998)
"Ifosfamide alone was given as a 24-h infusion at doses ranging from 5 to 7."5.28Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma. ( Hawkins, RE; Mansi, JL; Wiltshaw, E, 1990)
"To determine if paclitaxel added to ifosfamide as first-line treatment for advanced uterine carcinosarcoma (CS) improves overall survival (OS), progression-free survival (PFS), response, and toxicity."5.12Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. ( Bitterman, P; Eaton, L; Filiaci, V; Homesley, HD; Kilgore, LC; Markman, M; Monk, BJ; Ueland, FR, 2007)
"Adjuvant ifosfamide and cisplatin after primary surgery for stage I or II carcinosarcoma of the uterus is tolerable."5.11Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. ( Carson, LF; Gallion, H; Kauderer, J; Lentz, SS; Sutton, G; Whitney, CW, 2005)
"The aims of this study were to substantiate the previously reported activity of ifosfamide in patients with advanced, persistent, or recurrent carcinosarcoma (mixed mesodermal sarcoma) of the uterus, and to determine whether the addition of cisplatin results in an improved response or survival."5.09A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. ( Brunetto, VL; Hsiu, JG; Kilgore, L; Lentz, SS; McGehee, R; Olt, G; Soper, JT; Sorosky, J; Sutton, G, 2000)
"This is a Phase II groupwide study of the Gynecologic Oncology Group (GOG) to determine the toxicity and efficacy of a combination of ifosfamide and doxorubicin in patients with advanced or metastatic leiomyosarcomas of the uterus who had not received other chemotherapy."5.08Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study. ( Blessing, JA; Malfetano, JH; Sutton, G, 1996)
"In advanced stage metastatic uterine carcinosarcoma as well as recurrent disease adjuvant combination, chemotherapy with ifosfamide should be considered."4.89Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. ( Bryant, A; Das, N; Galaal, K; Godfrey, K; Kucukmetin, A; Lopes, AD; Naik, R; van der Heijden, E, 2013)
" In the primary treatment/ first line therapy of advanced stage metastatic uterine carcinosarcoma, as well as in recurrent disease, adjuvant combination chemotherapy with ifosfamide and paclitaxel should be considered."4.87Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. ( Bryant, A; Galaal, K; Godfrey, K; Kucukmetin, A; Naik, R, 2011)
"A retrospective study to evaluate six cycles of cisplatin 40 mg/m2 on day 1 and ifosfamide 1,200 mg/m2 daily on days 1 to 4 with Mesna every four weeks as first line treatment for 29 patients with a diagnosis of uterine carcinosarcoma."3.83Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( Abu-Khalaf, MM; Azodi, M; Hatzis, C; Higgins, S; Lin, K; Ratner, E; Raza, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Wang, H, 2016)
"To report two cases of recurrent uterine sarcoma that developed ifosfamide-induced encephalopathy (IIE) with successful management."3.76Ifosfamide-induced encephalopathy in patients with uterine sarcoma. ( Chang, FW; Liu, YL; Tsai, SH; Yu, MH, 2010)
"Our study corroborates GOG 150 results, and shows that paclitaxel-carboplatin appears to be an efficacious adjuvant chemotherapy regimen for completely resected uterine carcinosarcoma."3.74A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. ( Abu-Rustum, NR; Aghajanian, CA; Alektiar, KM; Hensley, ML; Iasonos, A; Makker, V; Zhou, Q, 2008)
"Our data suggest a potential role for anthracycline- and ifosfamide-containing chemotherapy in the adjuvant setting for early-stage uterine sarcomas."3.74Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience. ( Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Markaki, S; Papadimitriou, CA; Rodolakis, A; Voulgaris, Z; Zorzou, MP, 2007)
"To report the experience of a single institution in the south of Israel with doxorubicin and ifosfamide-mesna in patients with advanced/recurrent uterine sarcomas."3.73Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. ( Piura, B; Rabinovich, A, 2005)
"Between 1992 and 1999, 13 consecutive patients with completely resected moderate- to high-grade uterine sarcoma received three cycles of adjuvant ifosfamide (1."3.70Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. ( Belinson, JL; Kennedy, AW; Kushner, DM; Markman, M; Rybicki, LA; Webster, KD, 2000)
" In this article we report the first case of methemoglobinemia in a patient with metastatic uterine leiomyosarcoma, after infusion of ifosfamide chemotherapy."3.70Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. ( Govert, JA; Hadjiliadis, D, 2000)
"The purpose of this study was to evaluate the activity of ifosfamide (isophosphamide) in patients with advanced or recurrent leiomyosarcoma not previously exposed to chemotherapy."3.68Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. ( Barrett, RJ; Blessing, JA; McGehee, R; Sutton, GP, 1992)
"Uterine sarcomas are rare tumors."2.72Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus. ( Fietkau, R; Gerber, B; Klautke, G; Kortmann, B; Reimer, T, 2006)
"The response rate of 26 patients with ovarian cancer was 30."2.69[Ifosfamide combination chemotherapy for advanced gynecologic malignancies]. ( Li, X; Liu, L; Wu, L, 2000)
"Of 21 patients with testicular tumors who could be evaluated, 10 (47%) achieved a CR."2.68High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. ( André, T; Bonnak, H; Bouleuc, C; Donsimoni, R; Esteso, A; Firmin, C; Gerota, J; Izrael, V; Lotz, JP; Merad, Z, 1995)
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies."2.67Gynecologic Oncology Group experience with ifosfamide. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1990)
"Among gynecologic cancers, ovarian cancer is treated with chemotherapy as a routine practice."2.41[Gynecologic cancer-evidenced based chemotherapy]. ( Ochiai, K, 2000)
" Based on these findings, the author established a consecutive low-dose CDDP dosing method, which possibly could deliver a higher therapeutic index compared with the bolus-dosing method."2.40[Consecutive low-dose cisplatin-based chemotherapy for gynecologic malignancies]. ( Shimizu, Y, 1997)
"Ifosfamide was ineffective as adjuvant chemotherapy and there was aggressive tumor growth while the patient was on this regimen."2.38Myxoid leiomyosarcoma of the uterus. ( d'Ablaing, G; Kunzel, KE; Mills, NZ; Muderspach, LI, 1993)
"In epithelial ovarian cancer, responses were observed in eight (20%) of 41 evaluable patients, with three (7%) complete responses."2.38Gynecologic Oncology Group studies with ifosfamide. ( Blessing, JA; Homesley, H; Manetta, A; McGuire, W; Sutton, GP, 1992)
"Carcinosarcoma is a rare cancer, and its prognosis is poor."1.56Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. ( Ebata, T; Fujiwara, K; Fujiwara, Y; Hasegawa, K; Kato, T; Nishikawa, T; Noguchi, E; Shimomura, A; Sudo, K; Tamura, K; Yonemori, K, 2020)
"Early-stage uterine sarcomas are managed by hysterectomy + bilateral salpingo-oophorectomy according to menopausal status and histology; lymphadenectomy is not indicated in patients without bulky nodes, and morcellation must be avoided."1.56Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia). ( Aristei, C; Biondetti, PR; Cananzi, FCM; Casali, P; Ciccarone, F; Colombo, N; Comandone, A; Corvo', R; De Iaco, P; Dei Tos, AP; Donato, V; Ferrandina, G; Fiore, M; Gadducci, A; Gronchi, A; Guerriero, S; Infante, A; Lorusso, D; Odicino, F; Pirronti, T; Quagliuolo, V; Sanfilippo, R; Scambia, G; Testa, AC; Zannoni, GF, 2020)
"Uterine mullerian adenosarcoma is a rare tumor without specific clinical symptoms and signs."1.36[Mullerian adenosarcoma of the uterus: A clinicopathologic analysis of 9 cases]. ( Guo, LN; Han, XY; Huang, HF; Pan, LY; Sheng, K; Wan, XR; Xiang, Y, 2010)
"A case of uterine rhabdomyosarcoma is presented."1.31Rhabdomyosarcoma of the corpus of the uterus: a case report. ( Moerman, PH; Scheidt, P; Vergote, I, 2000)
" So we compared VAC protocol and ifosfamiide for toxic effects."1.30Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide). ( Erman, O; Simşek, T; Trak, B; Uner, M; Zorlu, GC, 1998)
"The authors report a case of encephalopathy after treatment with ifosfamide treated by a methylene blue infusion."1.29[Treatment of ifosfamide induced encephalopathy with methylene-blue]. ( Dreyfus, G; Eftekari, P; Ferrero, JM; Largillier, R; Namer, M, 1995)
"Ifosfamide alone was given as a 24-h infusion at doses ranging from 5 to 7."1.28Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma. ( Hawkins, RE; Mansi, JL; Wiltshaw, E, 1990)
"Ifosfamide (IFX) has activity in a number of gynaecological malignancies and was selected for evaluation in this disease."1.28A phase II study of ifosfamide in endometrial cancer. ( Barton, C; Blackledge, G; Buxton, EJ; Meanwell, CA; Mould, JJ, 1990)
"Ifosfamide/mesna has activity in a wide range of gynecologic malignancies."1.28Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies. ( Berman, ML; Blessing, JA; Homesley, HD; Photopulos, G; Sutton, GP, 1989)
"Ifosfamide and mesna were administered to 77 patients with advanced malignancies."1.27Prediction of ifosfamide/mesna associated encephalopathy. ( Blackledge, G; Blake, AE; Honigsberger, L; Kelly, KA; Meanwell, CA, 1986)

Research

Studies (76)

TimeframeStudies, this research(%)All Research%
pre-19909 (11.84)18.7374
1990's20 (26.32)18.2507
2000's25 (32.89)29.6817
2010's17 (22.37)24.3611
2020's5 (6.58)2.80

Authors

AuthorsStudies
Su, MH1
Wu, HH1
Huang, HY1
Lee, NR1
Chang, WH1
Lin, SC1
Chen, YJ1
Wang, PH3
Powell, MA1
Filiaci, VL1
Hensley, ML2
Huang, HQ1
Moore, KN1
Tewari, KS1
Copeland, LJ1
Secord, AA2
Mutch, DG1
Santin, A1
Warshal, DP1
Spirtos, NM1
DiSilvestro, PA1
Ioffe, OB2
Miller, DS1
Yang, ST1
Ebata, T1
Yonemori, K1
Nishikawa, T2
Sudo, K1
Shimomura, A1
Noguchi, E1
Fujiwara, Y1
Kato, T1
Hasegawa, K2
Fujiwara, K4
Tamura, K1
Ferrandina, G1
Aristei, C1
Biondetti, PR1
Cananzi, FCM1
Casali, P1
Ciccarone, F1
Colombo, N2
Comandone, A1
Corvo', R1
De Iaco, P1
Dei Tos, AP1
Donato, V1
Fiore, M1
Gadducci, A2
Gronchi, A1
Guerriero, S1
Infante, A1
Odicino, F1
Pirronti, T1
Quagliuolo, V1
Sanfilippo, R1
Testa, AC1
Zannoni, GF1
Scambia, G1
Lorusso, D2
Assi, T1
El Rassy, E1
Abi-Tayeh, G1
Sader-Ghorra, C1
Abadjian, G1
Eid, R1
Moussa, T1
Farhat, F1
Kattan, J1
Galaal, K2
van der Heijden, E1
Godfrey, K2
Naik, R2
Kucukmetin, A2
Bryant, A2
Das, N1
Lopes, AD1
Mancari, R1
Signorelli, M1
Carinelli, S1
De Ponti, E1
Sesana, S1
Corso, S1
Chiappa, V1
Lissoni, AA1
Martinelli, F1
Mancini, M1
Sarno, I1
Ditto, A1
Raspagliesi, F1
Hadoux, J1
Rey, A2
Duvillard, P2
Lhommé, C2
Balleyguier, C1
Haie-Meder, C2
Morice, P1
Tazi, Y1
Leary, A1
Larue, C1
Pautier, P2
Grignani, G1
Martín-Broto, J1
Schuler, M1
Reichardt, P1
Dandamudi, RK1
Aslam, S1
Walji, N1
El-Modir, A1
Fernando, I1
Dickson, EL1
Vogel, RI1
Gehrig, PA1
Pierce, S1
Havrilesky, L1
Dottino, J1
Fader, AN1
Ricci, S1
Geller, MA1
Matsuo, K1
Takazawa, Y1
Ross, MS1
Elishaev, E1
Podzielinski, I1
Yunokawa, M1
Sheridan, TB1
Bush, SH1
Klobocista, MM1
Blake, EA1
Takano, T1
Matsuzaki, S1
Baba, T1
Satoh, S1
Shida, M1
Ikeda, Y1
Adachi, S1
Yokoyama, T1
Takekuma, M1
Hazama, Y1
Kadogami, D1
Moffitt, MN1
Takeuchi, S1
Nishimura, M1
Iwasaki, K1
Ushioda, N1
Johnson, MS1
Yoshida, M1
Hakam, A1
Li, SW1
Richmond, AM1
Machida, H1
Mhawech-Fauceglia, P1
Ueda, Y1
Yoshino, K1
Yamaguchi, K1
Oishi, T1
Kajiwara, H1
Yasuda, M1
Kawana, K1
Suda, K1
Miyake, TM1
Moriya, T1
Yuba, Y1
Morgan, T1
Fukagawa, T1
Wakatsuki, A1
Sugiyama, T1
Pejovic, T1
Nagano, T1
Shimoya, K1
Andoh, M1
Shiki, Y1
Enomoto, T1
Sasaki, T1
Mikami, M1
Shimada, M1
Konishi, I1
Kimura, T1
Post, MD1
Shahzad, MM1
Im, DD1
Yoshida, H1
Omatsu, K1
Ueland, FR2
Kelley, JL1
Karabakhtsian, RG1
Roman, LD1
Abu-Khalaf, MM1
Raza, MA1
Hatzis, C1
Wang, H1
Lin, K1
Higgins, S1
Ratner, E1
Silasi, DA1
Azodi, M1
Rutherford, TJ1
Santin, AD1
Schwartz, PE1
Higgins, SC1
Zakashansky, K1
Bovbjerg, DH1
Hagopian, G1
Makker, V1
Abu-Rustum, NR1
Alektiar, KM1
Aghajanian, CA1
Zhou, Q1
Iasonos, A1
Han, XY1
Xiang, Y1
Guo, LN1
Sheng, K1
Wan, XR1
Huang, HF1
Pan, LY1
Liu, YL1
Tsai, SH1
Chang, FW1
Yu, MH1
Minobe, S1
Todo, Y1
Suzuki, Y1
Aoyagi, Y1
Umazume, T1
Okamoto, K1
Kato, H1
Einstein, MH1
Klobocista, M1
Hou, JY1
Lee, S1
Mutyala, S1
Mehta, K1
Reimers, LL1
Kuo, DY1
Huang, GS1
Goldberg, GL1
Chang, CC1
Wu, CC1
Floquet, A1
Gladieff, L1
Bompas, E1
Ray-Coquard, I1
Piperno-Neumann, S1
Selle, F2
Guillemet, C1
Weber, B1
Largillier, R2
Bertucci, F1
Opinel, P1
Duffaud, F1
Reynaud-Bougnoux, A1
Delcambre, C1
Isambert, N1
Kerbrat, P1
Netter-Pinon, G1
Pinto, N1
Ramondetta, LM2
Burke, TW1
Jhingran, A2
Schmandt, R1
Bevers, MW1
Wolf, JK1
Levenback, CF1
Broaddus, R1
Sutton, G3
Kauderer, J1
Carson, LF1
Lentz, SS2
Whitney, CW1
Gallion, H1
Dusenbery, KE1
Potish, RA1
Argenta, PA1
Judson, PL1
Piura, B1
Rabinovich, A1
Jeon, IS1
Lee, SM1
Ruiz Tovar, J1
Reguero Callejas, ME1
Arano Bermejo, JI1
Capote Armas, LF1
González-Palacios Martínez, F1
Cabañas Navarro, L1
Kortmann, B1
Reimer, T1
Gerber, B1
Klautke, G1
Fietkau, R1
Moreno Antón, F1
Casado Herraez, A1
Puente Vázquez, J1
Gómez Díaz, R1
Aragoncillo, P1
Díaz-Rubio García, E1
Homesley, HD3
Filiaci, V1
Markman, M2
Bitterman, P1
Eaton, L1
Kilgore, LC1
Monk, BJ1
Skubitz, KM1
Manivel, JC1
Papadimitriou, CA1
Zorzou, MP1
Markaki, S1
Rodolakis, A1
Voulgaris, Z1
Bozas, G1
Kastritis, E1
Bamias, A1
Gika, D1
Dimopoulos, MA1
Wolfson, AH1
Brady, MF1
Rocereto, T1
Mannel, RS1
Lee, YC1
Futoran, RJ1
Cohn, DE1
Brunello, A1
Basso, U1
Rossi, E1
Stefani, M1
Ghiotto, C1
Marino, D1
Crivellari, G1
Monfardini, S1
Kohno, I1
Kazuta, M1
Miyao, J1
Kunimi, N1
Kawamoto, M1
Tanimura, T1
Sekiba, K1
Ferrero, JM1
Eftekari, P1
Dreyfus, G1
Namer, M1
Garris, PD1
Gallup, DG1
Melton, K1
Lotz, JP2
André, T2
Donsimoni, R1
Firmin, C1
Bouleuc, C2
Bonnak, H1
Merad, Z1
Esteso, A1
Gerota, J1
Izrael, V2
Kunzel, KE1
Mills, NZ1
Muderspach, LI1
d'Ablaing, G1
Droz, JP1
Biron, P1
Blessing, JA6
Malfetano, JH1
Psikakos, G1
Papanicolaou, A1
Boutis, L1
Goutzioulis, M1
Makedos, G1
Papanicolaou, N1
Péne, F1
Gattegno, B1
Bazelly, B1
Houry, S1
Chapiro, J1
Gligorov, J1
Mollenkopf, A1
du Bois, A1
Meerpohl, HG1
Shimizu, Y1
van Besien, K1
Verschraegen, C1
Mehra, R1
Giralt, S1
Kudelka, AP1
Edwards, CL1
Piamsonboom, S1
Termrungruanglert, W1
Champlin, R1
Kavanagh, JJ1
Yuan, CC1
Chao, HT1
Wang, HM1
Hirota, Y2
Miyamura, K1
Hayata, T1
Miyakawa, I1
Simşek, T1
Uner, M1
Trak, B1
Erman, O1
Zorlu, GC1
Ochiai, K1
Kushner, DM1
Webster, KD1
Belinson, JL1
Rybicki, LA1
Kennedy, AW1
Hadjiliadis, D1
Govert, JA1
Scheidt, P1
Moerman, PH1
Vergote, I1
Edmonson, JH1
Brunetto, VL1
Kilgore, L1
Soper, JT1
McGehee, R2
Olt, G1
Sorosky, J1
Hsiu, JG1
Tsuda, H1
Maed, K1
Hashiguchi, Y1
Inoue, T1
Kobayashi, Y1
Umesaki, N1
Yamamoto, K1
Li, X1
Liu, L1
Wu, L1
Postovsky, S1
Beck, D1
Ben-Izhak, O1
Arush, MW1
Sutton, GP5
Manetta, A1
Homesley, H1
McGuire, W1
Barrett, RJ1
Hamaguchi, K1
Komai, K1
Sakihama, H1
Okura, N1
Nagasue, N2
Nishida, T2
Yakushiji, M2
Photopulos, G3
Berman, ML2
Hawkins, RE1
Wiltshaw, E1
Mansi, JL1
Barton, C1
Buxton, EJ1
Blackledge, G3
Mould, JJ2
Meanwell, CA3
Rosenshein, N1
DiSaia, PJ1
Blake, AE2
Latief, TN1
Blake, DR1
Shaw, IC1
Honigsberger, L2
Spooner, D1
Williams, AC1
Kelly, KA1
Kishi, N1
Imaishi, K1
Tateno, N1
Matsumura, T1
Loehrer, PJ1
Einhorn, LH1
Williams, SD1
Sawada, M1
Inagaki, M1
Hongo, J1
Ozaki, M1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, P[NCT00954174]Phase 3637 participants (Actual)Interventional2009-08-17Active, not recruiting
Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)[NCT02993705]Phase 245 participants (Actual)Interventional2017-02-22Completed
"A Pilot Phase II Trial of Adjuvant Radiation Therapy Sandwiched Between Ifosfamide in Patients With Mixed Mesodermal Tumors"[NCT00231842]Phase 230 participants (Actual)Interventional2003-02-28Completed
A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus[NCT00003128]Phase 3166 participants (Anticipated)Interventional1997-11-30Completed
A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus[NCT00002546]Phase 3216 participants (Anticipated)Interventional1993-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Duration of Progression-free Survival

Measured in months from randomization to last contact or the earlier of the date of progression or death. (NCT00954174)
Timeframe: Approximately 9 years and 7 months

Interventionmonths (Median)
Regimen I - Uterine Carcinsarcoma Subjects16.3
Regimen II - Uterine Carcinsarcoma Subjects11.7
Regimen III - Non-uterine Carcinsarcoma Subjects14.6
Regimen IV - Non-uterine Carcinsarcoma Subjects10.3

Overall Survival

Measured in months from randomization to last contact or death. Primary analysis was restricted to the eligible uterine carcinosarcoma cohort. (NCT00954174)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 115 months.

Interventionmonths (Median)
Regimen I- Uterine Carcinsarcoma Subjects37.3
Regimen II - Uterine Carcinsarcoma Subjects29

Patient Reported Peripheral Neuropathy Symptoms - Baseline

Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 11 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). . The Ntx score ranges 0-44 with a large score suggesting less peripheral neuropathy symptoms. Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life. (NCT00954174)
Timeframe: Baseline (Pre cycle 1)

Interventionunits on a scale-baseline (Mean)
Regimen I - Uterine and Non-Uterine Subjects40.2
Regimen II - Uterine and Non-Uterine Subjects41.0

Patient-Reported Quality of Life (QOL) - Baseline

Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for endometrial cancer (FACT-En TOI). The FACT-En TOI is a scale for assessing general QOL of endometrial cancer patients. The FACT-En TOI score ranges 0-120 with a large score suggesting better QOL. Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life. (NCT00954174)
Timeframe: Baseline - Prior to study treatment

Interventionunits on a scale (time point) (Mean)
Regimen I - Uterine and Non-Uterine Subjects96.2
Regimen II - Uterine and Non-Uterine Subjects97.5

Incidence of Adverse Events as Assessed by CTCAE Version 3.0

Maximum grade experienced among all treated and eligible patients. The grades are described by severity. Grade 1 is the lowest (most mild) and Grade 5 being death (most severe). Adverse events were analyzed across cohorts since disease site was considered independent of AEs. (NCT00954174)
Timeframe: Patients were assessed for adverse events during active protocol treatment and up to 30 days after the last cycle of treatment on the protocol.

,
InterventionParticipants (Count of Participants)
Grade 1Grade 2Grade 3Grade 4Grade 5
Regimen I - Uterine and Non-Uterine Subjects3221071306
Regimen II - All Uterine and Non-Uterine Subjects38097613

Patient Reported Quality of Life (QOL) - Post Baseline

Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for endometrial cancer (FACT-En TOI). The FACT-En TOI is a scale for assessing general QOL of endometrial cancer patients. The FACT-En TOI score ranges 0-120 with a large score suggesting better QOL. Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life. (NCT00954174)
Timeframe: Prior to cycle 3, Prior to cycle 6, 30 weeks post cycle 1.

,
Interventionunits on a scale (time point) (Least Squares Mean)
Pre-cycle 3Pree-cycle 630 weeks post cycle 1
Regimen I - Uterine and Non-Uterine Subjects93.391.698.0
Regimen II - Uterine and Non-Uterine Subjects93.391.697.6

Patient-reported Peripheral Neuropathy Symptoms - Post Baseline

Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 11 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). The Ntx score ranges 0-44 with a large score suggesting less peripheral neuropathy symptoms.Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life. (NCT00954174)
Timeframe: Prior to cycle 3, Prior to cycle 6, 30 weeks post cycle 1

,
Interventionunits on a scale (Least Squares Mean)
Prior to cycle 3Prior to cycle 630 weeks post cycle 1
Regimen I - Uterine and Non-Uterine Subjects37.234.134.8
Regimen II - Uterine and Non-Uterine Subjects37.034.234.9

Cycles With Hematologic Toxicities

Out of 162 planned cycles, a total of 138 cycles (85%) were administered. Number of cycles during which participants with grades 3 and 4 experienced hematologic toxicities are reported. Most of the toxicities were self-limiting. (NCT00231842)
Timeframe: 2 years

,
InterventionCycles (Number)
NeutropeniaAnemiaThrombocytopenia
Grade 3 Toxicity1166
Grade 4 Toxicity1402

Reviews

10 reviews available for ifosfamide and Cancer of the Uterus

ArticleYear
Chemotherapy-induced differentiation to cure botryoid rhabdomyosarcoma: a case report and review of the literature.
    European journal of gynaecological oncology, 2017, Volume: 38, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Dactinomycin; Desmin; F

2017
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
    The Cochrane database of systematic reviews, 2013, Feb-28, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Carcinosarcoma; Chemotherapy, Adjuvant; Female; Humans; Ifosfamid

2013
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
    The Cochrane database of systematic reviews, 2011, Jan-19, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Carcinosarcoma; Chemotherapy, Adjuvant; Female; Humans; Ifosfamid

2011
On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Abdominal Neoplasms; Antineoplastic Agents; Brachytherapy; Chemotherapy, Adjuvant; Combined Modality

2005
Giant cell tumor of the uterus: case report and response to chemotherapy.
    BMC cancer, 2007, Mar-14, Volume: 7

    Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal

2007
Myxoid leiomyosarcoma of the uterus.
    Gynecologic oncology, 1993, Volume: 48, Issue:2

    Topics: Female; Humans; Ifosfamide; Leiomyosarcoma; Middle Aged; Mitotic Index; Uterine Neoplasms

1993
[Consecutive low-dose cisplatin-based chemotherapy for gynecologic malignancies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin;

1997
[Gynecologic cancer-evidenced based chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Evidence-Based Medicine; Femal

2000
Secondary thyroid carcinoma after treatment for clear cell carcinoma of the uterus: case report and review of the literature.
    Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin;

2001
Gynecologic Oncology Group studies with ifosfamide.
    Seminars in oncology, 1992, Volume: 19, Issue:6 Suppl 12

    Topics: Adenocarcinoma; Carcinoma; Clinical Trials, Phase II as Topic; Endometrial Neoplasms; Female; Genita

1992

Trials

14 trials available for ifosfamide and Cancer of the Uterus

ArticleYear
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 03-20, Volume: 40, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Disease-Free Sur

2022
Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma.
    Gynecologic oncology, 2012, Volume: 124, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother

2012
A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:4

    Topics: Adult; Aged; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Do

2013
A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets.
    Gynecologic oncology, 2003, Volume: 90, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfamide;

2003
Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2005, Volume: 96, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chem

2005
Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2006, Volume: 182, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Respons

2006
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-10, Volume: 25, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin

2007
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-10, Volume: 25, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin

2007
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-10, Volume: 25, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin

2007
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-10, Volume: 25, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin

2007
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
    Gynecologic oncology, 2007, Volume: 107, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap

2007
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
    Gynecologic oncology, 2007, Volume: 107, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap

2007
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
    Gynecologic oncology, 2007, Volume: 107, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap

2007
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
    Gynecologic oncology, 2007, Volume: 107, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap

2007
High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
    Cancer, 1995, Feb-01, Volume: 75, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carb

1995
Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: a Gynecologic Oncology Group study.
    Gynecologic oncology, 1996, Volume: 62, Issue:2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined

1996
The ICE regimen (ifosfamide, carboplatin, etoposide) for the treatment of germ-cell tumors and metastatic trophoblastic disease.
    Bone marrow transplantation, 1996, Volume: 18 Suppl 1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Th

1996
A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.
    Gynecologic oncology, 2000, Volume: 79, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother

2000
[Ifosfamide combination chemotherapy for advanced gynecologic malignancies].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2000, Volume: 22, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; I

2000
Gynecologic Oncology Group experience with ifosfamide.
    Seminars in oncology, 1990, Volume: 17, Issue:2 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy;

1990

Other Studies

52 other studies available for ifosfamide and Cancer of the Uterus

ArticleYear
Comparing paclitaxel-platinum with ifosfamide-platinum as the front-line chemotherapy for patients with advanced-stage uterine carcinosarcoma.
    Journal of the Chinese Medical Association : JCMA, 2022, 02-01, Volume: 85, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Femal

2022
Abandon ifosfamide-based regimen and use paclitaxel-carboplatin regimen for the treatment of uterine carcinosarcoma.
    Journal of the Chinese Medical Association : JCMA, 2022, 05-01, Volume: 85, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Female; Humans; Ifosfam

2022
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
    Oncology, 2020, Volume: 98, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Docetaxel;

2020
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia).
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 139

    Topics: Adenosarcoma; Anthracyclines; Antineoplastic Agents; Chemotherapy, Adjuvant; Consensus; Dacarbazine;

2020
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
    Gynecologic oncology, 2014, Volume: 133, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemothera

2014
Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino

2014
Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplatin; Combined Modali

2015
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
    Future oncology (London, England), 2015, Volume: 11, Issue:11 Suppl

    Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; C

2015
Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
    Anticancer research, 2015, Volume: 35, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma

2015
A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
    Gynecologic oncology, 2015, Volume: 139, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma

2015
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:7

    Topics: Adult; Aged; Carcinoma; Carcinosarcoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Human

2016
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.
    European journal of gynaecological oncology, 2016, Volume: 37, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherap

2016
Unexpected vomiting in a woman contemplating a second course of chemotherapy for carcinosarcoma of the uterus.
    Journal of pain and symptom management, 2008, Volume: 36, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherapy, Adjuvant; Cisplatin; F

2008
A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.
    Gynecologic oncology, 2008, Volume: 111, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Diseas

2008
[Mullerian adenosarcoma of the uterus: A clinicopathologic analysis of 9 cases].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:1

    Topics: Adenosarcoma; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv

2010
Ifosfamide-induced encephalopathy in patients with uterine sarcoma.
    Taiwanese journal of obstetrics & gynecology, 2010, Volume: 49, Issue:1

    Topics: Aged; Antineoplastic Agents, Alkylating; Female; Humans; Ifosfamide; Methylene Blue; Middle Aged; Ne

2010
Mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy for uterine leiomyosarcoma: a report of two cases.
    The journal of obstetrics and gynaecology research, 2011, Volume: 37, Issue:6

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubic

2011
Beau's lines.
    QJM : monthly journal of the Association of Physicians, 2013, Volume: 106, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Female; Humans; Ifosfamide; Middle A

2013
Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas.
    European journal of gynaecological oncology, 2005, Volume: 26, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Mesn

2005
Multimodal treatment using surgery, radiotherapy, and chemotherapy in a patient with a perivascular epithelioid cell tumor of the uterus.
    Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Doxorubicin; Epith

2005
Malignant mixed Mullerian tumors.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemo

2006
Cardiac metastasis from uterine leiomyosarcoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidin

2006
Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience.
    European journal of gynaecological oncology, 2007, Volume: 28, Issue:2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined

2007
Eleven years: the long and winding road.
    Gynecologic oncology, 2007, Volume: 107, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherapy, Adjuvant; Cisplatin; C

2007
Ifosfamide-related encephalopathy in elderly patients : report of five cases and review of the literature.
    Drugs & aging, 2007, Volume: 24, Issue:11

    Topics: Abdominal Neoplasms; Aged; Antidotes; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che

2007
[Clinical studies of ifosfamide for gynecological malignancies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:5

    Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Evaluation; Female; Humans; I

1983
[Treatment of ifosfamide induced encephalopathy with methylene-blue].
    Bulletin du cancer, 1995, Volume: 82, Issue:7

    Topics: Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Female; Humans; Ifosfamide; Methylene Blue;

1995
Long-term remission of previously resistant choriocarcinoma with a combination of etoposide, ifosfamide, and cisplatin.
    Gynecologic oncology, 1995, Volume: 57, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Drug Resistance;

1995
High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
    Cancer, 1995, Jul-01, Volume: 76, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com

1995
The use of combined chemotherapy for the treatment of advanced sarcoma of the uterus.
    European journal of gynaecological oncology, 1996, Volume: 17, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C

1996
[Sequential course and prospective management of ifosfamide-induced multi-organ toxicity].
    Geburtshilfe und Frauenheilkunde, 1996, Volume: 56, Issue:10

    Topics: Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modal

1996
Complete remission of refractory gestational trophoblastic disease with brain metastases treated with multicycle ifosfamide, carboplatin, and etoposide (ICE) and stem cell rescue.
    Gynecologic oncology, 1997, Volume: 65, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined Modality

1997
The VIP regimen effective treatment to refractory choriocarcinoma: a case report.
    Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1997, Volume: 59, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Etoposide; Female

1997
Treatment of metastatic uterine leiomyosarcoma with cisplatin, pirarubicin, and ifosfamide.
    Gynecologic and obstetric investigation, 1997, Volume: 44, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Humans; Ifosf

1997
Toxicity of chemotherapeutical protocols in the treatment of uterine sarcomas (Vincristine, actinomycin D, Cyclophosphamide VAC versus ifosfamide).
    European journal of gynaecological oncology, 1998, Volume: 19, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad

1998
Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
    Gynecologic oncology, 2000, Volume: 78, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Female; Humans; Ifosfamide;

2000
Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide.
    Chest, 2000, Volume: 118, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Biomarkers; Diagnosis, Differential; Female; Humans; Ifosfamide;

2000
Rhabdomyosarcoma of the corpus of the uterus: a case report.
    European journal of gynaecological oncology, 2000, Volume: 21, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dactinomycin; Female; Humans; Hysterectomy; I

2000
Are we there yet?
    Gynecologic oncology, 2000, Volume: 79, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Female; Humans; Ifosfamid

2000
Malignant rhabdoid tumour of the uterine cervix.
    BJOG : an international journal of obstetrics and gynaecology, 2001, Volume: 108, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etopo

2001
Report on carcinogenesis bioassay of isophosphamide.
    American Industrial Hygiene Association journal, 1978, Volume: 39, Issue:6

    Topics: Animals; Carcinogens; Cyclophosphamide; Cystitis; Dogs; Female; Hair; Ifosfamide; Lymphoma; Male; Ma

1978
Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    American journal of obstetrics and gynecology, 1992, Volume: 166, Issue:2

    Topics: Adult; Aged; Agranulocytosis; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Ifosfamide

1992
Chemotherapeutic approach to uterine papillary serous carcinoma.
    Asia-Oceania journal of obstetrics and gynaecology, 1990, Volume: 16, Issue:4

    Topics: Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Carc

1990
Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Leio

1990
A phase II study of ifosfamide in endometrial cancer.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26 Suppl

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Ifosfamide;

1990
Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.
    Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Ci

1989
Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).
    American journal of obstetrics and gynecology, 1989, Volume: 161, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Fem

1989
Encephalopathy associated with ifosphamide/mesna therapy.
    Lancet (London, England), 1985, Feb-16, Volume: 1, Issue:8425

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Cyclophosphamide; Female; Humans; If

1985
Prediction of ifosfamide/mesna associated encephalopathy.
    European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Electroencephalography; Female; Huma

1986
A preliminary study of a combination chemotherapy with ifosfamide, adriamycin and cisplatin for endometrial carcinoma.
    Nihon Sanka Fujinka Gakkai zasshi, 1988, Volume: 40, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubi

1988
VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Female; Humans; Ifosfami

1986
[Ifosfamide, cisplatin, adriamycin combination chemotherapy in gynecologic cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administra

1987